If you have been reading about visceral adipose tissue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
===== Pharmacodynamics ===== The melanocortin receptor agonist proposes to activate multiple receptor subtypes nonselectively, with the highest affinity with MC1R, then MC4R, MC3R, MC5R, and MC2R receptors. As MC4R receptors are present on neurons in the central nervous system, a function in modulating brain pathways is suggested, albeit a precise mechanism remains unknown.
==== External ==== Starfish are deuterostome animals, like the chordates. A 2014 analysis of 219 genes from all classes of echinoderms gives the following phylogenetic tree. The times at which the clades diverged are shown under the labels in millions of years ago (mya).
In Russia, bribes were made as payments to foreign agents with phony Moscow addresses and off-shore bank accounts. These foreign agents aimed to win government contracts by influencing Russia's Ministry of Health. In Vietnam, Bio-Rad's Singapore subsidiary regularly paid bribes to Vietnamese government officials. A regional sales manager raised concerns about this practice, and in response another employee proposed employing a middleman to pay the bribes instead. In Thailand, Bio-Rad acquired Diamed Thailand with very little due diligence. Diamed Thailand was running an existing scheme to bribe government officials, which Bio-Rad's Asia Pacific General Manager later found out about in March 2008. They initiated an investigation, which confirmed the bribery was occurring, however did not instruct Diamed Thailand to stop the bribery and the payments continued until 2010. In 2017, Bio-Rad paid $55 million to settle cases with the Department of Justice and the Securities and Exchange Commission for violating the Foreign Corrupt Practices Act (FCPA). The company was accused of failing to prevent or detect bribes to foreign officials, and for falsifying its books to hide these bribes as legitimate expenses.
Trump won the Electoral College with 312 electoral votes to Harris' 226. He prevailed in all of the seven swing states (Pennsylvania, Georgia, North Carolina, Michigan, Arizona, Wisconsin, and Nevada). In addition, Trump won the national popular vote with a plurality of 49.8%; Harris received 48.3%. Cedric Richmond, co-chair the Harris campaign, announced on election night that Harris would not be speaking as originally planned. In the early hours of November 6, the day after the election, Trump was projected to win the election, and he declared victory at his Mar-a-Lago estate. Harris later conceded to Trump via a phone call, and publicly conceded the election to Trump that afternoon during a speech at Howard University.
Sources: en.wikipedia.org
=== Imaging === Ultrasound, particularly duplex ultrasound, is the most usual and widely used way of viewing veins in the diagnosis of venous disease. Venography is an invasive procedure that uses a catheter to deliver a contrast agent in giving an X-ray of veins. An augmented reality healthcare application is a near-infrared vein finder that films subcutaneous veins, and projects their image either onto a screen or onto the person's skin.
The 2013 Cochrane Collaboration review (updated in 2026) on physical exercise for depression noted that, based upon limited evidence, it is moderately more effective than a control intervention and comparable to psychological or antidepressant drug therapies. Smaller effects were seen in more methodologically rigorous studies. Three subsequent 2014 systematic reviews that included the Cochrane review in their analysis concluded with similar findings: one indicated that physical exercise is effective as an adjunct treatment with antidepressant medication; the other two indicated that physical exercise has marked antidepressant effects and recommended the inclusion of physical activity as an adjunct treatment for mild–moderate depression and mental illness in general. These studies also found smaller effect sizes in more methodologically rigorous studies. All four systematic reviews called for more research in order to determine the efficacy or optimal exercise intensity, duration, and modality. A 2025 systematic review on the effectiveness of rock climbing for depression reported that indoor bouldering combined with mindfulness exercises may be an effective, clinically meaningful, safe, and sustainable adjunctive intervention for adults with moderate depression. However, the review found insufficient data to determine whether it was superior to other established treatments.
In December 2023, ActionAid reported that there was little water for washing and some shelters only had one shower for every 700 individuals and one toilet for every 150. UNICEF announced on 7 March 2024 that they were distributing wellbeing kits to adolescent girls in Rafah, who reported being unable to "shower more than once a week. The shelters are crowded with people, and there is little water. It is difficult to maintain personal hygiene". It was reported in late February 2024 that there were 690,000 menstruating women and children in Gaza, that have limited access to menstrual hygiene supplies. Some women and children have utilized period blocking pills, but those can be hard to find and many are unable to take them for medical reasons. One girl sheltering in a UNRWA school in Maghazi told reporters that she had begun washing used pads to reuse them, while another indicated that due to the stress of the war she had been having her period more often, about twice a month. A mom of five daughters told reporters that they were all utilizing Pampers diapers for their periods, and had to cut the diapers in half due to costs while others have utilized rags, old clothes, towels or corners of tents causing chafing and skin infections. In June 2024, children suffered from intestinal infections and hepatitis C or A, due to the destruction of Gaza's water supply and sanitation systems.
=== Nana Mary === Nana Mary is played by Shelley Winters. Nana Mary is Beverly's mother and Roseanne and Jackie's grandmother, and first appears at a family barbecue in season three. She has another daughter named Sonya. She makes several appearances from season three onward, mostly during family occasions. She is a brash but caring, outspoken, lovable retiree who gambles with her grandchildren. Unlike Bev, she is popular with the family. She also disagrees with Bev in certain situations, such as siding with Jackie when Bev urges her to marry Fred, and revealing that she had two abortions, upsetting Bev. She outsmarts Bev and torments her, much to the amusement of Roseanne and Jackie, who usually endure the same treatment from Bev. Her character is often a comic relief for the family, as well as offering a balance between Roseanne and Jackie's relationship with their mother, and Bev's relationship with Nana Mary. She was promiscuous in her youth and claims that as a globe-trotting free spirit she knew Pablo Picasso, Louis Armstrong, Ernest Hemingway, Fidel Castro, and Meyer Lansky, among others. Mary had Bev with another man before marrying her deceased husband, Marvin. She tells Bev she was very young when she gave birth, admits to not knowing who the father is, and avoided the subject until Bev demanded to finally know. Mary is a fan of a local radio call-in show that revolves around sex: "If I don't call, they worry," she claims.
== Further reading == Biot, René. (1962). The Enigma of the Stigmata. Hawthorn Books. Carroll, Robert Todd. (2003). Stigmata. In The Skeptic's Dictionary. Wiley. ISBN 978-0-471-27242-7 Harrison, Ted. (1994). Stigmata: A Medieval Phenomenon in a Modern Age. St Martins Press. ISBN 0-312-11372-2 Mazzoni, Cristina. (1996). Saint Hysteria: Neurosis, Mysticism, and Gender in European Culture. Cornell University Press. ISBN 0-8014-3229-4 Nickell, Joe. (1993). Looking for a Miracle: Weeping Icons, Relics, Stigmata, Visions & Healing Cures. Prometheus Books. ISBN 1-57392-680-9 Radford, Benjamin. (2014). What is Stigmata?. LiveScience. Retrieved 12 May 2016. Wilson, Ian. (1988). The Bleeding Mind: An Investigation into the Mysterious Phenomena of Stigmata. Weidenfeld & Nicolson. ISBN 0-297-79099-4 Yarom, Nitza. (1992). Body, Blood, and Sexuality: A Psychoanalytic Study of St. Francis' Stigmata and Their Historical Context. Peter Lang Publisher. Van Osselaer, Tina; Graus, Andrea; Rossi, Leonardo; Smeyers, Kristof (12 October 2020). The Devotion and Promotion of Stigmatics in Europe c. 1800–1950, between Saints and Celebrities (PDF). Numen Book Series-Studies in the History of Religions. Vol. 167. Leiden, Boston: Brill. p. 487. ISBN 978-90-04-43935-1. ISSN 0169-8834. LCCN 2020031449. Archived (PDF) from the original on September 9, 2021.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.